0.00Open0.05Pre Close0 Volume1.26K Open Interest5.00Strike Price0.00Turnover173.22%IV96.12%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1070Delta0.1587Gamma51.50Leverage Ratio-0.0042Theta0.0002Rho5.51Eff Leverage0.0012Vega
Esperion Therapeutics Stock Discussion
someone loaded 520k at close 👀👀👀👀
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid).
The analysis showed patients with Peripheral Artery Disease (PAD) tak...
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...
No comment yet